Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study

References

• Henry DH Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1993 4 275 278
   Google Scholar
• Knight K Wade S Balducci L Prevalence and outcomes of anemia in cancer: a systematic review of the literature Am J Med 2004 116 Suppl 7A 11S 26S 15050883
   PubMed Web of Science ®Google Scholar
• Cella D Kallich J McDermott A Xu X The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials Ann Oncol 2004 15 6 979 986 15151958
   PubMed Web of Science ®Google Scholar
• Harrison LB Chadha M Hill RJ Hu K Shasha D Impact of tumor hypoxia and anemia on radiation therapy outcomes Oncologist 2007 6 492 508
   Web of Science ®Google Scholar
• Demetri GD Kris M Wade J Degos L Cella D Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group J Clin Oncol 1998 16 10 3412 3425 9779721
   PubMed Web of Science ®Google Scholar
• Gabrilove JL Cleeland CS Livingston RB Sarokhan B Winer E Einhorn LH Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 2001 19 11 2875 2882 11387360
   PubMed Web of Science ®Google Scholar
• Littlewood TJ Bajetta E Nortier JW Vercammen E Rapoport B Epoetin Alfa Study Group Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 2001 19 11 2865 2874 11387359
   PubMed Web of Science ®Google Scholar
• Glaspy J Bukowski R Steinberg D Taylor C Tchekmedyian S Vadhan-Raj S Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group J Clin Oncol 1997 15 3 1218 1234 9060566
   PubMed Web of Science ®Google Scholar
• Henke M Laszig R Rübe C Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 2003 362 9392 1255 1260 14575968
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B BEST Investigators and Study Group Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol 2003 4 8 459 460 12901958
   PubMed Web of Science ®Google Scholar
• Bohlius J Langensiepen S Schwarzer G Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis J Natl Cancer Inst 2005 97 7 489 498 15812074
   PubMedGoogle Scholar
• Macdougall IC Strategies for iron supplementation: oral versus intravenous Kidney Int Suppl 1999 69 S61 S66 10084288
   PubMed Web of Science ®Google Scholar
• KDOQI KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target Am J Kidney Dis 2007 50 3 471 530 17720528
   PubMed Web of Science ®Google Scholar
• Cazzola M Mercuriali F Brugnara C Use of recombinant human erythropoietin outside the setting of uremia Blood 1997 89 12 4248 4267 9192747
   PubMed Web of Science ®Google Scholar
• Weiss G Goodnough LT Anemia of chronic disease N Engl J Med 2005 352 10 1011 1023 15758012
   PubMed Web of Science ®Google Scholar
• Andrews NC Anemia of inflammation: the cytokine-hepcidin link J Clin Invest 2004 113 9 1251 1253 15124013
   PubMed Web of Science ®Google Scholar
• Hedenus M Birgegård G Näsman P Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study Leukemia 2007 21 4 627 632 17252006
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P Farris A Del Prete S Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha J Clin Oncol 2008 26 10 1619 1625 18375891
   PubMed Web of Science ®Google Scholar
• Bastit L Vandebroek A Altintas S Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia J Clin Oncol 2008 26 10 1611 1618 18375890
   PubMed Web of Science ®Google Scholar
• Auerbach M Silberstein PT Webb RT Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia Am J Hematol 2010 85 9 655 663 20661916
   PubMed Web of Science ®Google Scholar
• Henry DH Dahl NV Auerbach M Tchekmedyian S Laufman LR Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy Oncologist 2007 12 2 231 242 17296819
   PubMed Web of Science ®Google Scholar
• Steensma DP Management of anemia in patients with cancer Curr Oncol Rep 2004 6 4 297 304 15161584
   PubMedGoogle Scholar
• Wun T Law L Harvey D Sieracki B Scudder SA Ryu JK Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin Cancer 2003 98 7 1514 1520 14508840
   PubMed Web of Science ®Google Scholar
• Shao W Edelman LS Sullivan DJ Nelson EW Shelby J Long-term cytokine alterations following allogeneic blood transfusion J Investig Med 1998 46 4 161 167
   Web of Science ®Google Scholar
• Santin AD Bellone S Parrish RS Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix Gynecol Obstet Invest 2003 56 1 28 34 12867765
   PubMed Web of Science ®Google Scholar
• Fishbane S Frei GL Maesaka J Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation Am J Kidney Dis 1995 26 1 41 46 7611266
   PubMed Web of Science ®Google Scholar
• Fishbane S Safety in iron management Am J Kidney Dis 2003 41 Suppl 5 18 26 12776310
   PubMedGoogle Scholar
• Steinmetz T Tschechne B Harlin O Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia Ann Oncol 2013 24 2 475 482 23071262
   PubMed Web of Science ®Google Scholar
• Kowdley KV Iron, hemochromatosis, and hepatocellular carcinoma Gastroenterology 2004 127 5 Suppl 1 S79 S86 15508107
   PubMed Web of Science ®Google Scholar
• Besarab A Frinak S Yee J An indistinct balance: the safety and efficacy of parenteral iron therapy J Am Soc Nephrol 1999 10 9 2029 2043 10477157
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K Regidor DL McAllister CJ Michael B Warnock DG Time-dependent associations between iron and mortality in hemodialysis patients J Am Soc Nephrol 2005 16 10 3070 3080 16033854
   PubMed Web of Science ®Google Scholar